|
BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies. |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine; Merck |
Speakers' Bureau - AstraZeneca; Merck; Merrimack |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine; Gilead Sciences |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |